[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP066940A - Antagonistas del receptor de acetilcolina muscarínico - Google Patents

Antagonistas del receptor de acetilcolina muscarínico

Info

Publication number
ECSP066940A
ECSP066940A EC2006006940A ECSP066940A ECSP066940A EC SP066940 A ECSP066940 A EC SP066940A EC 2006006940 A EC2006006940 A EC 2006006940A EC SP066940 A ECSP066940 A EC SP066940A EC SP066940 A ECSP066940 A EC SP066940A
Authority
EC
Ecuador
Prior art keywords
muscarinic
antagonists
acetilcoline
receiver
methods
Prior art date
Application number
EC2006006940A
Other languages
English (en)
Inventor
I Dramane Laine
Michael Robert Palovich
Brent W Mccleland
Christopher E Neipp
Sonia M Thomas
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066940(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ECSP066940A publication Critical patent/ECSP066940A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/452Piperidinium derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

Se proporcionan antagonistas del receptor de acetilcolina muscarínico y métodos para utilizarlos.
EC2006006940A 2004-04-27 2006-10-20 Antagonistas del receptor de acetilcolina muscarínico ECSP066940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27
PCT/US2005/014386 WO2005104745A2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists

Publications (1)

Publication Number Publication Date
ECSP066940A true ECSP066940A (es) 2006-12-20

Family

ID=35242158

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006940A ECSP066940A (es) 2004-04-27 2006-10-20 Antagonistas del receptor de acetilcolina muscarínico

Country Status (38)

Country Link
US (9) US7498440B2 (es)
EP (3) EP1740177B1 (es)
JP (2) JP5014121B2 (es)
KR (2) KR101037026B1 (es)
CN (2) CN1976701A (es)
AP (1) AP2213A (es)
AR (1) AR050902A1 (es)
AU (1) AU2005237576B2 (es)
BE (1) BE2014C063I2 (es)
BR (1) BRPI0510170B8 (es)
CA (2) CA2755954C (es)
CY (3) CY1113196T1 (es)
DK (2) DK2570128T3 (es)
EA (2) EA021994B1 (es)
EC (1) ECSP066940A (es)
ES (2) ES2600405T3 (es)
HK (1) HK1102423A1 (es)
HR (2) HRP20120832T1 (es)
HU (2) HUE031304T2 (es)
IL (1) IL178152A (es)
LT (1) LT2570128T (es)
LU (1) LU92565I2 (es)
MA (1) MA28631B1 (es)
MX (1) MXPA06012405A (es)
MY (1) MY144753A (es)
NL (1) NL300694I2 (es)
NO (3) NO338959B1 (es)
NZ (1) NZ549997A (es)
PE (1) PE20060259A1 (es)
PL (2) PL2570128T3 (es)
PT (2) PT2570128T (es)
SG (1) SG186597A1 (es)
SI (2) SI1740177T1 (es)
TW (1) TWI363759B (es)
UA (1) UA95768C2 (es)
UY (1) UY28871A1 (es)
WO (1) WO2005104745A2 (es)
ZA (1) ZA200608565B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045914A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
UY28567A1 (es) * 2003-10-17 2005-05-31 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
JP2007528420A (ja) * 2004-03-11 2007-10-11 グラクソ グループ リミテッド 新規m3ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005094251A2 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
US7384946B2 (en) * 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
DE602005009158D1 (de) * 2004-04-05 2008-10-02 Samaritan Pharmaceuticals Inc Anti-hiv-chinuklidinverbindungen
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
US7932247B2 (en) * 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2009503099A (ja) * 2005-08-02 2009-01-29 グラクソ グループ リミテッド M3ムスカリン性アセチルコリン受容体アンタゴニスト
JP2009504768A (ja) * 2005-08-18 2009-02-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
AU2007242851A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
CA2659539A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
PE20091563A1 (es) 2008-02-06 2009-11-05 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
CL2009000248A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo [3,4-b] piridin-5-il, inhibidores de la fosfodiesterasa de tipo iv (pde4) y antagonista de receptores muscarinicos de acetilcolina (machr); composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles en el tratamiento de enferemedades respiratorias y alergicas
UY31637A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
HRP20241000T3 (hr) 2009-02-26 2024-10-25 Glaxo Group Limited Farmaceutske formulacije koje sadrže 4-{(1r)-2-[(6-{2-[(2,6-diklorobenzil)oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenol
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドGlaxo Group Limited Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
CA2759476C (en) 2009-04-30 2018-10-09 Julie Nicole Hamblin Novel compounds
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
JP2013512878A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド 新規化合物
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
US8742131B2 (en) * 2010-01-28 2014-06-03 Theron Pharmaceuticals, Inc. 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
CN102946868B (zh) * 2010-06-22 2014-10-29 奇斯药制品公司 包含抗毒蕈碱药的干粉制剂
RS54286B1 (en) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited POLYMORPHS AND SALTS N- [5- [4- (5 - {[(2R, 6S) -2,6-DIMETHYL-4-MORPHOLINYL] METHYL} -1,3-OXAZOL-2-yl) -1H-INDAZZOL- 6-IL] -2 (methyloxy) -3-pyridinyl] -methanesulfonamide
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
KR20140041699A (ko) * 2011-06-08 2014-04-04 글락소 그룹 리미티드 우메클리디늄 및 코르티코스테로이드를 포함하는 조합물
AU2012266540A1 (en) 2011-06-08 2014-01-09 Glaxo Group Limited Dry powder inhaler compositions comprising umeclidinium
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
CA2881935A1 (en) * 2012-08-15 2014-02-20 Glaxo Group Limited Process for preparing a 1-(2-haolethyl)-4-piperidine carboxylate intermediate useful in the synthesis of umeclidinium bromide
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
RU2641285C2 (ru) * 2013-07-13 2018-01-17 Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд Соединения хинина, способ их получения и их медицинское применение
SG11201600045UA (en) * 2013-07-30 2016-02-26 Glaxosmithkline Ip Dev Ltd Topical compositions for treatment of excessive sweating and methods of use thereof
JP6475707B2 (ja) 2013-10-17 2019-02-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 呼吸器疾患の治療のためのpi3k阻害剤
WO2015055690A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
MX2016014859A (es) 2014-05-12 2017-06-27 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
ES2959699T3 (es) 2014-05-28 2024-02-27 Glaxosmithkline Ip Dev Ltd Furoato de fluticasona en el tratamiento de la EPOC
US10023535B2 (en) 2014-11-03 2018-07-17 Olon S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技(上海)有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
BR112022019245A2 (pt) 2020-03-26 2022-11-16 Glaxosmithkline Ip Dev Ltd Inibidores de catepsina para prevenir ou tratar infecções virais
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
AU2021264829B2 (en) * 2020-04-26 2024-02-01 Beijing Showby Pharmaceutical Co., Ltd. Crystal of M receptor antagonist as well as preparation method therefor and application thereof
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (es) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
IN160851B (es) 1982-10-08 1987-08-08 Glaxo Group Ltd
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
NL8601949A (nl) 1985-07-30 1987-02-16 Glaxo Group Ltd Inrichtingen voor het toedienen van medicamenten aan patienten.
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
JP2001505576A (ja) 1996-12-02 2001-04-24 ジョージタウン ユニバーシティ トロパン誘導体類及びそれらの合成方法
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1353919B1 (en) * 2000-12-28 2006-07-26 Almirall Prodesfarma AG Novel quinuclidine derivatives and medicinal compositions containing the same
EP1438309A1 (en) 2001-10-17 2004-07-21 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
CA2466344A1 (en) * 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
IL162596A0 (en) * 2001-12-20 2005-11-20 S A L V A T Lab Sa 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists
US6696462B2 (en) * 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
EP1613307A4 (en) 2003-04-07 2008-03-12 Glaxo Group Ltd M SB 3 / SB MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
AR048573A1 (es) 2003-07-17 2006-05-10 Glaxo Group Ltd Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima
AR045914A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
AR045913A1 (es) 2003-07-17 2005-11-16 Glaxo Group Ltd Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
MY143366A (en) 2003-10-14 2011-04-29 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
UY28567A1 (es) 2003-10-17 2005-05-31 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
CA2543858C (en) 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
AR046783A1 (es) 2003-12-03 2005-12-21 Glaxo Group Ltd Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima
UY28645A1 (es) 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005086873A2 (en) 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2007528420A (ja) 2004-03-11 2007-10-11 グラクソ グループ リミテッド 新規m3ムスカリン性アセチルコリン受容体アンタゴニスト
US20070185090A1 (en) 2004-03-17 2007-08-09 Jakob Busch-Petersen Muscarinic acetylchoine receptor antagonists
US7384946B2 (en) 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005094251A2 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
WO2005094835A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1732923A2 (en) 2004-04-07 2006-12-20 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1747219A4 (en) 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
AR048976A1 (es) 2004-05-28 2006-06-14 Glaxo Group Ltd Compuesto derivado de alcohol terciario de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
JP2008505118A (ja) 2004-06-30 2008-02-21 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
US20070293531A1 (en) 2004-08-05 2007-12-20 Jakob Busch-Petersen Muscarinic Acetycholine Receptor Antagonists
WO2006017767A2 (en) 2004-08-06 2006-02-16 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2006050239A2 (en) 2004-10-29 2006-05-11 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2006055503A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US7932247B2 (en) 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
JP2009503099A (ja) 2005-08-02 2009-01-29 グラクソ グループ リミテッド M3ムスカリン性アセチルコリン受容体アンタゴニスト
WO2007016650A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2009504768A (ja) 2005-08-18 2009-02-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
US20160002220A1 (en) 2016-01-07
US8853404B2 (en) 2014-10-07
UA95768C2 (ru) 2011-09-12
PL2570128T3 (pl) 2017-09-29
NO20065417L (no) 2006-12-29
CN1976701A (zh) 2007-06-06
EA021994B1 (ru) 2015-10-30
HUE031304T2 (hu) 2017-07-28
KR101152032B1 (ko) 2012-06-11
AU2005237576A1 (en) 2005-11-10
PL1740177T3 (pl) 2012-12-31
BRPI0510170B8 (pt) 2021-05-25
US9144571B2 (en) 2015-09-29
WO2005104745A2 (en) 2005-11-10
TWI363759B (en) 2012-05-11
US8575347B2 (en) 2013-11-05
EP1740177A4 (en) 2010-05-05
WO2005104745A3 (en) 2006-08-03
ES2392848T3 (es) 2012-12-14
CA2755954A1 (en) 2005-11-10
BE2014C063I2 (es) 2024-08-08
KR20070015412A (ko) 2007-02-02
CA2564742C (en) 2012-01-10
MY144753A (en) 2011-10-31
LU92565I9 (es) 2019-01-17
NZ549997A (en) 2010-10-29
TW200605887A (en) 2006-02-16
EP3111936A1 (en) 2017-01-04
KR101037026B1 (ko) 2011-05-25
EP2570128A1 (en) 2013-03-20
SG186597A1 (en) 2013-01-30
EP1740177B1 (en) 2012-08-08
JP2007534769A (ja) 2007-11-29
US7498440B2 (en) 2009-03-03
ES2600405T3 (es) 2017-02-08
JP5398871B2 (ja) 2014-01-29
CY1113196T1 (el) 2015-12-09
CY1118082T1 (el) 2017-06-28
MA28631B1 (fr) 2007-06-01
US8183257B2 (en) 2012-05-22
HUS1400053I1 (hu) 2017-07-28
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
DK1740177T3 (da) 2012-10-29
BRPI0510170B1 (pt) 2018-12-18
NO338959B1 (no) 2016-11-07
HRP20161385T1 (hr) 2016-12-02
IL178152A (en) 2011-05-31
PT1740177E (pt) 2012-11-02
AP2213A (en) 2011-03-01
CA2564742A1 (en) 2005-11-10
NO2017017I1 (no) 2017-05-04
CA2755954C (en) 2014-02-18
CY2014043I2 (el) 2015-12-09
EA201100019A1 (ru) 2011-12-30
EA015033B1 (ru) 2011-04-29
US20140371264A1 (en) 2014-12-18
CY2014043I1 (el) 2015-12-09
US9045469B2 (en) 2015-06-02
KR20110010841A (ko) 2011-02-07
US20120157491A1 (en) 2012-06-21
LU92565I2 (fr) 2014-12-02
JP5014121B2 (ja) 2012-08-29
NO2017018I2 (no) 2018-05-14
DK2570128T3 (en) 2016-11-07
UY28871A1 (es) 2005-11-30
AP2006003746A0 (en) 2006-10-31
BRPI0510170A (pt) 2007-10-02
CN102040602A (zh) 2011-05-04
SI2570128T1 (sl) 2016-11-30
HK1102423A1 (en) 2007-11-23
NL300694I1 (es) 2015-12-29
PE20060259A1 (es) 2006-03-25
ZA200608565B (en) 2019-12-18
AU2005237576B2 (en) 2012-01-12
MXPA06012405A (es) 2007-01-17
EP1740177A2 (en) 2007-01-10
US8309572B2 (en) 2012-11-13
US7488827B2 (en) 2009-02-10
LT2570128T (lt) 2016-10-10
EP2570128B1 (en) 2016-08-10
IL178152A0 (en) 2006-12-31
EA200601991A1 (ru) 2007-02-27
JP2012162559A (ja) 2012-08-30
US20150238470A1 (en) 2015-08-27
SI1740177T1 (sl) 2012-12-31
US20130030015A1 (en) 2013-01-31
AR050902A1 (es) 2006-12-06
US20090124653A1 (en) 2009-05-14
HRP20120832T1 (hr) 2012-11-30
PT2570128T (pt) 2016-10-07
ES2392848T4 (es) 2014-10-01
US20070185155A1 (en) 2007-08-09
NL300694I2 (es) 2015-12-29
NO2017018I1 (no) 2017-05-04

Similar Documents

Publication Publication Date Title
ECSP066940A (es) Antagonistas del receptor de acetilcolina muscarínico
UY28598A1 (es) Antagonistas de receptores de acetilcolina muscarinicos
UY27927A1 (es) Antagonistas del receptor muscarínico m3 de acetilcolina
MY143366A (en) Muscarinic acetylcholine receptor antagonists
ECSP066486A (es) Antagonistas de receptores de acetilcolina muscarínicos ii
WO2007022351A3 (en) Muscarinic acetylcholine receptor antagonists
TW200600093A (en) M3 muscarinic acetylcholine receptor antagonists
NO20063636L (no) Muskariniske acetylkolinrecptoorantagonister
WO2007016639A3 (en) M3 muscarinic acetylcholine receptor antagonists
WO2007016650A3 (en) M3 muscarinic acetylcholine receptor antagonists
UY28646A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
UY28645A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200633715A (en) Medical combinations
MXPA06000662A (es) Antagonistas del receptor muscarinico de acetilcolina.
TW200519108A (en) Muscarinic acetylcholine receptor antagonists
TW200519109A (en) Muscarinic acetylcholine receptor antagonists
WO2006065788A3 (en) Novel muscarinic acetylcholine receptor antagonists
TW200633706A (en) Medical combinations
TW200606161A (en) Muscarinic acetylcholine receptor antagonists
WO2006055553A3 (en) Novel m3 muscarinic acetylcholine receptor antagonists
TW200600500A (en) M3 muscarinic acetylcholine receptor antagonists
WO2006055503A3 (en) Novel m3 muscarinic acetylcholine receptor antagonists
WO2006050239A3 (en) Muscarinic acetylcholine receptor antagonists
WO2005112644A3 (en) Muscarinic acetylcholine receptor antagonists
WO2006017768A3 (en) Muscarinic acetylcholine receptor antagonists